Scots first to receive breakthrough immunotherapy for lung cancer
![](/46/pdcnewsitem/04/16/65/BMS.jpg)
Eligible patients in Scotland will be the first in the UK to access this life-extending treatment and will be ahead of those patients in England and Wales.
Bristol-Myers Squibb (BMS) has announced that the Scottish Medicines Consortium (SMC) has recommended the breakthrough cancer immunotherapy Opdivo (nivolumab) to treat NHS patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) whose disease has progressed after prior chemotherapy. The SMC has recognised the survival and quality of life benefit nivolumab offers these very ill patients and its decision means that Scotland is the first country within the UK to approve the treatment for use on the NHS. Scotland now joins a number of other European countries including Germany, Greece and Sweden in making this life-extending treatment option available for squamous NSCLC patients.
Nivolumab represents the first major treatment innovation in this type of lung cancer for almost 20 years and is the first in a new class of medicines (PD-1 immune checkpoint inhibitors) for the treatment of lung cancer patients. It has an innovative mode of action that works by harnessing the ability of the immune system to fight this type of advanced lung cancer as well as advanced forms of skin and kidney cancer.
While today’s recommendation is positive news for patients in Scotland, the assessment of nivolumab by NICE is currently ongoing, meaning that the treatment remains unavailable for those patients living in England; it also remains unavailable in Wales and Northern Ireland.
“Today’s decision gives Scottish NHS patients the chance to benefit from one of the biggest treatment advances in this type of lung cancer for decades and one that has the potential to change future survival expectations,” said Johanna Mercier, General Manager of BMS UK & Ireland. “While this decision is positive news for lung cancer patients in Scotland, it will further compound the disappointment of patients in the rest of the UK, who are still waiting for access to this medicine. This demonstrates how antiquated the current UK system for reviewing new cancer medicines is and the disparity that it creates for patients and their families. We call on the UK Government to bring an end to the outdated processes that, in 2016, still mean that a person’s ability to access a cancer medicine on the NHS is determined not by their needs, but by where they live.”
In a pivotal Phase III study of 272 patients, treatment in the nivolumab arm (n=135) was shown to achieve significantly superior survival rates with 42% of patients still alive at one-year compared to 24% of those treated with docetaxel (n=137). Severe treatment-related adverse events occurred less frequently with nivolumab (out of 131 patients treated with nivolumab, 7% had grade 3-4 adverse events compared to 55% of 129 patients treated with docetaxel).
Today’s decision focuses on patients with a specific form of advanced lung cancer which has spread and is incurable. In 2014, around 5,300 people were diagnosed with all types of lung cancer in Scotland, with a majority of these patients diagnosed at an advanced stage; the prognosis for survival in these patients is poor. Approximately 10% of patients diagnosed with lung cancer in Scotland will survive 5 years or more. In 2014, approximately 4,100 people died from lung cancer,
which is almost equivalent to the amount of deaths from colorectal, breast, prostate and oesophageal cancers combined.Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance